Topiramate titration and tolerability

OBJECTIVE: To evaluate the tolerability and efficacy of two titration rates for topiramate initiated as adjunctive therapy in adults with partial-onset seizures, with or without secondary generalization, in a multicenter, double-blindtrial. METHODS: After a two-week baseline phase, 188 patients were randomized to either a 50/50 titration schedule (initial dosage 50 mg/d increased in 50-mg/d increments at weekly intervals; n = 95) or to a 100/200 titration schedule (initial dosage 100 mg/d increased by 100-200 mg/d at weekly intervals; n = 93). The maximum dosage of 400 mg/d was therefore achieved in eight weeks or three weeks, respectively. RESULTS: Compared with the 100/200 titration rate, the 50/50 titration rate significantly reduced the cumulative incidence of treatment-emergent adverse events (TEAEs) leading to changes in topiramate therapy (ie., dosage reductions, interruptions or discontinuations of therapy) (p = 0.048) and significantly reduced treatment interruptions or withdrawals due to TEAEs (p = 0.040). Mild or moderate effects involving the central nervous system were the most frequent adverse events. At the final visit, therapeutic responses were comparable in the 50/50 and 100/200 titration groups: median percent seizure reduction was 42% vs. 33%, proportion of patients with 250% seizure reduction was 42% vs. 38%, and proportion of patients with no seizures during double-blind treatment was 14% vs. 10%, respectively. Seizure frequency was substantially reduced from baseline during topiramate titration. At day 22, with the 50/50 titration group receiving 150 mg/d and the 100/200 titration group receiving 400 mg/d, the mean percent seizure reduction was 51% and 54%, respectively. CONCLUSIONS: Gradual initiation of topiramate therapy can significantly enhance patient tolerability without delaying therapeutic response.

This article has been cited by other articles:

				P Tfelt-Hansen, N. Bjarnason, C Dahlof, S Derry, E Loder, H Massiou, and for the Task Force on Adverse Events in Migraine T Evaluation and Registration of Adverse Events in Clinical Drug Trials in Migraine Cephalalgia, July 1, 2008; 28(7): 683 - 688. [Abstract] [Full Text] [PDF]

				D. K Naritoku, J. F Hulihan, L. K. Schwarzman, M. Kamin, and W. H Olson Effect of Cotherapy Reduction on Tolerability of Epilepsy Add-On Therapy: A Randomized Controlled Trial Ann. Pharmacother., March 1, 2005; 39(3): 418 - 423. [Abstract] [Full Text] [PDF]

				J. A. French, A. M. Kanner, J. Bautista, B. Abou-Khalil, T. Browne, C. L. Harden, W. H. Theodore, C. Bazil, J. Stern, S. C. Schachter, et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society Neurology, April 27, 2004; 62(8): 1261 - 1273. [Abstract] [Full Text] [PDF]

				J. Christensen, F. Andreasen, J. H. Poulsen, and M. Dam Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy Neurology, November 11, 2003; 61(9): 1210 - 1218. [Abstract] [Full Text] [PDF]

				W E. Dodson, M. Kamin, L. Kraut, W. H Olson, and S.-C. Wu Topiramate Titration to Response: Analysis of Individualized Therapy Study (TRAITS) Ann. Pharmacother., May 1, 2003; 37(5): 615 - 620. [Abstract] [Full Text] [PDF]

				M. D Privitera Phase IV Trials: A Wolf in Sheep's Clothing? Ann. Pharmacother., May 1, 2003; 37(5): 741 - 743. [Full Text] [PDF]

				S Forderreuther, M Mayer, and A Straube Authors' Reply: Treatment of Cluster Headache with Topiramate: Effects and Side-Effects in Five Patients Cephalalgia, February 1, 2003; 23(1): 70 - 70. [Full Text] [PDF]